Xspray Pharma AB (publ) (STO:XSPRAY)

Sweden flag Sweden · Delayed Price · Currency is SEK
49.25
-3.05 (-5.83%)
Aug 1, 2025, 5:29 PM CET
-5.83%
Market Cap1.83B
Revenue (ttm)n/a
Net Income (ttm)-260.07M
Shares Out37.14M
EPS (ttm)-7.52
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume27,863
Average Volume28,760
Open52.40
Previous Close52.30
Day's Range49.25 - 52.40
52-Week Range23.00 - 64.82
Beta0.53
RSI60.52
Earnings DateAug 6, 2025

About Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partn... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 27
Stock Exchange Nasdaq Stockholm
Ticker Symbol XSPRAY
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.